Intellectual Property India Publishes Patent Application for 'Therapeutic Regimens And Methods For Reducing Body Weight In A Subject With Fatty Liver Disease Using A GLP 1R And GCGR Agonist' Filed by Spitfire Pharma Llc

MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517034888 A) filed by Spitfire Pharma Llc, Gaithersburg, U.S.A., on April 9, for 'therapeutic regimens and methods for reducing body weight in a subject with fatty liver disease using a glp 1r and gcgr agonist.'

Inventor(s) include Browne Sarah K; Harris Matthew Scott; Suschak III John Joseph; Georges Bertrand Victor Gilbert; and Roberts M. Scott.

The application for the patent was published on June 13, under issue no. 24/2025.

According to the abstract released by the Intellectual Property India: "This disclosure relates to the once weekly dosing regimen of a dual GLP 1R and GCGR agonist formulations and methods of using the same for inducing weight loss in a human being with fatty liver disease wherein the human may or may not have other comorbidities such as type 2 diabetes and/or cardiovascular disease/disorder. The dual GLP 1R and GCGR agonist includes the peptide product of SEQ ID NO. 1 (pemvidutide)."

The patent application was internationally filed on Sept. 14, 2023, under International application No.PCT/US2023/074255.

Disclaimer: Curated by HT Syndication.